Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ibrutinib promising in subtype of DLBCL.

× No keyword cloud information.

5 in total

Review 1. Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors: Regan Stephenson; Ankur Singh
Journal: Adv Drug Deliv Rev Date: 2017-06-15 Impact factor: 15.470

2. Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Authors: Eva Gupta; Joseph Accurso; Jason Sluzevich; David M Menke; Han W Tun
Journal: Rare Tumors Date: 2015-12-29

3. Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma.

Authors: Xing Zhong; Zhiliang Liu; Qingfeng Luo; Jingao Li; Weiwei Zhang; Yuerong Shuang
Journal: Oncol Lett Date: 2021-02-02 Impact factor: 2.967

4. Expression of N⁶-methyladenosine (m⁶A) regulators correlates with immune microenvironment characteristics and predicts prognosis in diffuse large cell lymphoma (DLBCL).

Authors: Zucheng Xie; Meiwei Li; Haoyuan Hong; Qingyuan Xu; Zhendong He; Zhigang Peng
Journal: Bioengineered Date: 2021-12 Impact factor: 3.269

5. How Biophysical Forces Regulate Human B Cell Lymphomas.

Authors: F Apoorva; Alexander M Loiben; Shivem B Shah; Alberto Purwada; Lorena Fontan; Rebecca Goldstein; Brian J Kirby; Ari M Melnick; Benjamin D Cosgrove; Ankur Singh
Journal: Cell Rep Date: 2018-04-10 Impact factor: 9.423